APA (7th ed.) Citation

Monteith, D., Collins, E. C., Vandermeulen, C., Van Hecken, A., Raddad, E., Scherer, J. C., . . . de Hoon, J. (2017). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers. Frontiers in pharmacology, 8, 740. https://doi.org/10.3389/fphar.2017.00740

Chicago Style (17th ed.) Citation

Monteith, David, Emily C. Collins, Corinne Vandermeulen, Anne Van Hecken, Eyas Raddad, Joel C. Scherer, David Grayzel, Thomas J. Schuetz, and Jan de Hoon. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers." Frontiers in Pharmacology 8 (2017): 740. https://doi.org/10.3389/fphar.2017.00740.

MLA (9th ed.) Citation

Monteith, David, et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers." Frontiers in Pharmacology, vol. 8, 2017, p. 740, https://doi.org/10.3389/fphar.2017.00740.